The 2003 Canadian recommendations for dyslipidemia management: revisions are needed.
Manuel
Douglas G
DG
Institute for Clinical Evaluative Sciences, Toronto, Ont. doug.manuel@ices.on.ca
Tanuseputro
Peter
P
Mustard
Cameron A
CA
Schultz
Susan E
SE
Anderson
Geoffrey M
GM
Ardal
Sten
S
Alter
David A
DA
Laupacis
Andreas
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D002170:Canada; D008078:Cholesterol, LDL / Q000097:blood; D003327:Coronary Disease / Q000401:mortality / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D005102:Health Expenditures; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D012307:Risk Factors
D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents